Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25402282 | 1.00 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLBCA12 | |
| SCHEMBL25405281 | 1.00 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLBCA12 | |
| SCHEMBL25405122 | 0.81 | RAB9A (0.57) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL31597178 | 0.79 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL25406224 | 0.75 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL31597539 | 0.74 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL31699091 | 0.73 | AOC3 (0.35) | — | |
| SCHEMBL31699581 | 0.73 | AOC3 (0.35) | — | |
| SCHEMBL31699887 | 0.71 | AOC3 (0.35) | — | |
| SCHEMBL31699215 | 0.71 | AOC3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2023164234-A9 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023164234-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | RAB9A 1335/4885LMNA 798/4885ALDH1A1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.